Skip to main content

Table 3 Post therapy

From: Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: a multicenter, collaborative, open-label, phase II clinical study for the SBCCSG 35 investigators

 

n

PR

L-SD

SD

PD

NE

PDa

ADM/EPI + CPA

3

   

3

 

1

S1

3

  

3

  

1

PTX + BEV

23

5

1

9

5

3

 

ERI

3

1

  

1

1

2

DTX

1

   

1

  

EXE + EVE

1

   

1

  

CPA

1

   

1

  

None

1

      

Pembrolizumab

1

    

1

 

Rx to the whole brain

3

1

 

1

1

  
  1. a: Progressive disease in induction therapy
  2. ADM doxorubicin, EPI epirubicin, CPA cyclophosphamide, PTX paclitaxel, BEV bevacizumab, ERI eribulin, DTX docetaxel, EXE exemestane, EVE everolimus, Rx radiation, PR partial response, L-SD long-lasting stable disease, SD stable disease, PD progressive disease, NE not evaluable